Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $72

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ: KNSA ) with a Outperform and raises the price target from $59 to $72.